Fri Oct 31 11:54:27 SGT 2014  
    Yellow Fever Vaccine, Nigeria

Yellow Fever Vaccine, Nigeria

Summary

Yellow Fever Vaccine, Nigeria @beautynigeria_com: Live attenuated yellow fever virus vaccine jab/shot/injection schedule, to vaccinate against the Yellow fever virus, to immunise against Yellow fever

Keywords: Yellow Fever Vaccine Nigeria, Nigeria Yellow Fever Vaccine, Yellow Fever Vaccine.

Description

The 17D vaccine, which is based on a live, attenuated viral strain, is the only commercially available yellow fever vaccine. It is given as a single subcutaneous (or intramuscular) injection. Yellow fever vaccine is highly effective (approaching 100%). All individuals aged 9 months or older and living in countries or areas at risk should receive yellow fever vaccine.

Precautions and contraindications

With the exception of very rare cases of vaccine-associated neurotropic and viscerotropic disease (see below), the 17D vaccine is generally considered to be safe. However, some vaccine recipients develop mild systemic reactions, including myalgia and headache. Contraindications include true allergy to egg protein, immunodeficiency (congenital or acquired) and symptomatic HIV infection (Chapter 9). There is a theoretical risk of harm to the fetus if the vaccine is given during pregnancy and vaccination of nursing mothers should be avoided because of the risk for the transmission of 17D virus to and encephalitis in the breast-fed infant.These risks must be weighed against the risk to the mother of remaining unvaccinated and travelling to an area where exposure to YFV may occur. In general, unvaccinated pregnant or nursing women should be advised not to travel to such areas.

Hypersensitivity reactions are rare, particularly anaphylactic reactions. However, the vaccine is produced in embryonated chicken eggs and is contraindicated in persons with a history of oral egg intolerance or strong allergic reactions to egg-based products.

Encephalitis has been reported as a rare event following vaccination, principally in infants under 6 months of age. As a result, the vaccine is contraindicated in infants under 6 months of age and is not recommended for those aged 6–8 months, except during epidemics when the risk of YFV transmission may be very high.

Vaccine-associated viscerotropic disease is a recently described adverse event that on very rare occasions has occurred after the first immunization with the yellow fever 17D vaccine. Onset is within 10 days of vaccination and the pathological process is characterized by severe multi-organ failure and an overall case—fatality rate in excess of 60%. Known risk factors include a history of thymus disease (e.g. thymoma or thymectomy) and age ≥ 60 years. In the United Sates, the risk for people aged ≥ 70 years of contracting viscerotropic disease after receiving vaccination against yellow fever is estimated to be 2.4 cases/100 000 vaccine doses.

Increased incidence of vaccine-associated neurotropic disease (e.g. meningoencephalitis, acute disseminated encephalomyelitis and Guillain-Barré syndrome) has been reported in infants under 6 months of age and in vaccine recipients aged ≥60 years . The reported rate of vaccine-associated neurotropic disease in travellers from the United States and Europe ranges between 0.13 and 0.8 per 100 000 doses.

Yellow fever vaccination is required for travellers to certain countries and recommended for all travellers to countries or areas with risk of yellow fever transmission (see Country list and Annex 1). The risk to unvaccinated individuals who visit countries or areas where there may be yellow fever transmission is often greater than the risk of a vaccine-related adverse event. While yellow fever vaccination should be encouraged as a key prevention strategy, it is important to screen travel itineraries and carefully evaluate the potential risk of systemic illness after yellow fever vaccination. Great care should be exercised not to prescribe yellow fever vaccination to individuals who are not at risk of exposure to infection, based on an accurate assessment of the travel itinerary. Although vaccination is generally not recommended for travellers going to areas where the risk of exposure is low, any risk (e.g. as a result of prolonged travel or heavy exposure to mosquito bites) should be weighed against individual risk factors for vaccine-associated adverse events (e.g. altered immune status).

Type of vaccine: Live, attenuated

Number of doses: One dose of 0.5 ml

Booster: Currently every 10 years (if re-certification is needed)

Contraindications: Infants aged less than 6 months; history of allergy to egg or to any of the vaccine components, or hypersensitivity to a previous dose of the vaccine; thymoma or history of thymectomy, immunodeficiency from medication, disease or symptomatic HIV infection.

Adverse reactions: Rarely, neurological (encephalitis) or multi-organ failure resembling wild-type yellow fever

Before departure: International certificate of vaccination becomes valid 10 days after vaccination.

Recommended for: All travellers to countries and areas with risk of yellow fever transmission and when required by countries.

Special precautions: Not recommended for infants aged 6-8 months, except during epidemics when the risk of YF virus transmission may be very high. The risks and benefits of vaccination in this age group should be carefully considered before vaccination. The vaccine should be avoided during pregnancy or breastfeeding. However, pregnant or nursing women may be vaccinated during epidemics or if traveling to country or area a risk of transmission is unavoidable.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Yellow Fever Vaccine, Nigeria
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

References


Latest News

What Immunizations Can Pregnant and Postpartum Women Receive?
Mon, 27 Oct 2014 00:39:42 +0100 | PediatricEducation.org
Discussion

Live viral vaccines in transplanted patients.
Sun, 26 Oct 2014 12:35:03 +0100 | Swiss Medical Weekly
Authors: L'Huillier AG, Posfay Barbe K

Yellow fever
Fri, 24 Oct 2014 00:00:00 +0100 | Journal of Clinical Virology
, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of yellow fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of yellow fever, with an emphasis on recent changes in the distribution and incidence of the disease. (Source: Journal of Clinical Virology)

Yf-Vax (Yellow Fever Vaccine) - updated on RxList
Tue, 14 Oct 2014 07:00:00 +0100 | RxList - New and Updated Drug Monographs
(Source: RxList - New and Updated Drug Monographs)

Safety of immunization during pregnancy: A review of the evidence of selected inactivated and live attenuated vaccines.
Fri, 03 Oct 2014 00:00:00 +0100 | Vaccine
This report presents an overview of available evidence on pregnant women vaccination safety monitoring in pregnant women, from both published literature and ongoing surveillance programs. Safety data were reviewed for vaccines against diseases which increase morbidity in pregnant women, their fetus or infant as well as vaccines which are used in mass vaccination campaigns against diseases. They include inactivated seasonal and pandemic influenza, mono- and combined meningococcal polysaccharide and conjugated vaccines, tetanus toxoid and acellular pertussis combination vaccines, as well as monovalent or combined rubella, oral poliomyelitis virus and yellow fever vaccines. No evidence of adverse pregnancy outcomes has been identified from immunization of pregnant women with these vaccines.

In silico models for predicting vector control chemicals targeting Aedes aegypti.
Thu, 02 Oct 2014 00:00:00 +0100 | SAR and QSAR in Environmental Research
Authors: Devillers J, Lagneau C, Lattes A, Garrigues JC, Clémenté MM, Yébakima A

Vaccination in Elite Athletes
Wed, 01 Oct 2014 00:00:00 +0100 | Sports Medicine
Abstract

MEK/ERK activation plays a decisive role in yellow fever virus replication: Implication as an antiviral therapeutic target.
Fri, 19 Sep 2014 00:00:00 +0100 | Antiviral Research
Authors: Albarnaz JD, De Oliveira LC, Torres AA, Palhares RM, Casteluber MC, Rodrigues CM, Cardozo PL, De Souza AM, Pacca CC, Ferreira PC, Kroon EG, Nogueira ML, Bonjardim CA

Uganda: Yellow Fever Scam Exposed at Entebbe Airport
Fri, 12 Sep 2014 03:33:18 +0100 | AllAfrica News: Health and Medicine
[Observer]A sophisticated racket of workers at Entebbe International airport is minting millions of shillings daily from unsuspecting travellers to China by extorting money from them ostensibly to process a yellow fever vaccination certificate, an investigation by The Observer has revealed. (Source: AllAfrica News: Health and Medicine)

High prevalence of previous dengue virus infection among first-generation Surinamese immigrants in the Netherlands
Wed, 10 Sep 2014 00:00:00 +0100 | BMC Infectious Diseases
Conclusions: